Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
gliclazidum, gliclazida
Class :
Antidiabetics, Sulfonylureas
Brand Name :
No Data Available.
Synonyms :
gliclazidum, gliclazida
Class :
Antidiabetics, Sulfonylureas
AdultÂ
Dosage forms & StrengthsÂ
Modified-release tabletÂ
30mgÂ
60mgÂ
Immediate-release tabletÂ
80 mgÂ
For immediate-release tablet-
40-80 mg orally once daily with breakfast
Dose Modification
Increase the dose by 40-80 mg every 1-4 weeks if required to establish glycemic goals
Maintenance dose- 40-160 mg/day
Do not exceed more than 320 mg/day
For a dose more than 160 mg/day, administer it in a couple of divided doses
For modified-release tablet-
Initially 30 mg once daily with breakfast
Dose Modification
Increase the dose by 30 mg every 1-4 weeks if required to establish glycemic goals
Maintenance dose- 30-60 mg/day
Do not exceed more than 120 mg/day
Not suitable for pediatricsÂ
Refer to the adult dosingÂ
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of sulfonylureas
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of sulfonylureas
may increase the therapeutic efficacy of each other when combined
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
it may diminish the metabolism when combined with azelastine
When halometasone is used together with gliclazide, this leads to elevated risk or seriousness of hyperglycemia
may have an increased adverse/toxic effect when combined with alcohol
the efficacy of gliclazide can be raised when used in combination with sulfametopyrazine
When gliclazide is used together with diazoxide, this leads to reduction in therapeutic effectiveness of gliclazide
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with gliclazide, this leads to elevated hyperglycemia risk
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
it increases the effect of hypoglycemia of antidiabetic agents
may enhance the serum concentration of CYP2C9 inhibitors
may increase the hypoglycemic effect of beta blockers
hydrochlorothiazide/aliskirenÂ
may diminish the therapeutic effect of thiazide and thiazide like diuretics
may enhance the hypoglycemic effect of beta blockers
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
It may intensify the hypoglycemic effect of sulfonylureas
It has the potential to amplify the hypoglycemic impact of sulfonylureas
may have an increased adverse/toxic effect when combined with alcohol
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
lansoprazole, amoxicillin, and clarithromycin
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
bismuth subcitrate, metronidazole and tetracycline
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
The actions of gliclazide include the stimulation of insulin secretion from the beta cells in the pancreas and an increase in the sensitivity of target tissues, such as adipose tissue and muscle, to insulin. This results in increased glucose uptake and utilization in these tissues, which helps to lower blood sugar levels.Â
gliclazide also has some additional beneficial effects, such as improving endothelial function and reducing oxidative stress, which may contribute to its cardiovascular protective effects.Â
The spectrum of activity of gliclazide is primarily limited to the treatment of type 2 diabetes mellitus. It is not effective for the treatment of type 1 diabetes mellitus, a condition in which the body does not produce insulin at all, and it is not recommended for use in patients with diabetic ketoacidosis.Â
Frequency definedÂ
>10%Â
HypoglycemiaÂ
1-10%Â
HypertensionÂ
Nausea Â
Headache Â
Diarrhea Â
Vomiting Â
Dermatitis Â
Injection site pruritus Â
Dizziness Â
Injection site erythema Â
Constipation Â
Urinary tract infectionÂ
Viral infectionÂ
Frequency not definedÂ
Increased creatinine in serumÂ
Increased lactate dehydrogenaseÂ
gliclazide does not have a black box warning in the United States. However, it is important to note that gliclazide, like other sulfonylurea medications, may increase the risk of hypoglycemia (low blood sugar) and may not be suitable for all patients, particularly those with advanced age, impaired liver or kidney function, or other medical conditions.Â
Hypoglycemia can be a serious condition that may result in seizures, loss of consciousness, and even death in severe cases. Patients taking gliclazide should be advised to monitor their blood sugar levels regularly and to report any symptoms of hypoglycemia to their healthcare provider immediately.Â
Furthermore, gliclazide may also cause allergic reactions or skin rashes in some patients. If any signs of an allergic reaction or skin rash occur, patients should discontinue the medication and seek immediate medical attention.Â
gliclazide is contraindicated in patients with a history of hypersensitivity to gliclazide or other sulfonylurea medications. It should not be used in patients with type 1 diabetes mellitus, diabetic ketoacidosis, or severe liver or kidney dysfunction.Â
Caution should be exercised in patients with a history of hypoglycemia, as gliclazide may increase the risk of low blood sugar. It should also be used with caution in patients with adrenal or pituitary insufficiency, as well as in patients with severe infections, fever, or trauma, as these conditions may increase the demand for insulin and increase the risk of hypoglycemia.Â
gliclazide should be used with caution in elderly patients, as they may be more susceptible to hypoglycemia and may require lower doses of the medication.Â
Pregnancy consideration:Â Â
It is not secure to administer gliclazide during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available about the excretion of gliclazide in human breastmilk. Avoid using in lactating women.Â
Pregnancy category:Â
gliclazide is an oral antidiabetic medication that belongs to the sulfonylurea class. It works by stimulating the release of insulin from the beta cells in the pancreas, leading to increased uptake and utilization of glucose by peripheral tissues such as muscle and adipose tissue. This helps to lower blood sugar levels in patients with type 2 diabetes mellitus.Â
Gliclazide also has some additional beneficial effects, such as improving endothelial function and reducing oxidative stress, which may contribute to its cardiovascular protective effects.Â
The onset of action of gliclazide is rapid, with peak effects seen within 2-4 hours of administration. The duration of action is also relatively long, with a half-life of approximately 10 hours, allowing for once or twice-daily dosing.Â
Pharmacodynamics:Â
gliclazide is an antidiabetic medication that belongs to the sulfonylurea class. It acts primarily by stimulating the release of insulin from the beta cells of the pancreas, leading to increased uptake and utilization of glucose by peripheral tissues such as muscle and adipose tissue. This helps to lower blood sugar levels in patients with type 2 diabetes mellitus.Â
gliclazide also has additional beneficial effects, such as improving endothelial function, reducing oxidative stress, and decreasing platelet aggregation. These effects may contribute to the cardiovascular protective effects observed with gliclazide therapy.Â
The hypoglycemic effect of gliclazide is dose-dependent and may persist for up to 24 hours after a single dose. It is important to note that the risk of hypoglycemia (low blood sugar) increases with higher doses of gliclazide and may be more common in elderly patients or those with impaired liver or kidney function.Â
Pharmacokinetics:Â
AbsorptionÂ
It is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within 2-4 hours.Â
DistributionÂ
gliclazide is extensively bound to plasma proteins (up to 95%)Â
MetabolismÂ
It is primarily metabolized in the liver by cytochrome P450 enzymes, primarily CYP2C9 and CYP3A4. The metabolites are inactive and are excreted in the urine and fecesÂ
Elimination and ExcretionÂ
The elimination half-life of gliclazide is approximately 10 hours, allowing for once or twice-daily dosing. The dose of gliclazide may need to be adjusted in patients with impaired liver or kidney function, as these conditions may affect the metabolism and elimination of the medication.Â
gliclazide does not significantly affect the metabolism of other medications and has a low potential for drug interactions. However, caution should still be exercised when using gliclazide in combination with other medications, and any potential drug interactions should be discussed with a healthcare professional.
gliclazide is an oral medication that is typically taken once or twice daily with a meal. It is important to follow the dosing instructions provided by the healthcare provider, as the dose may need to be adjusted based on individual patient factors such as age, weight, kidney or liver function, and other medications being taken.Â
It is important to take gliclazide at the same time each day to maintain consistent blood levels of the medication. If a dose is missed, it should be taken as soon as possible, unless it is close to the time for the next dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed.Â
gliclazide should be taken with food to reduce the risk of hypoglycemia (low blood sugar), as food helps to slow the absorption of the medication and can reduce the likelihood of a rapid drop in blood sugar levelsÂ
Patient information leafletÂ
Generic Name: gliclazideÂ
Pronounced: glic-lae-zideÂ
Why do we use gliclazide?Â
gliclazide is used to treat type 2 diabetes mellitus, which is a condition characterized by high levels of sugar (glucose) in the blood due to the body’s inability to properly use insulin or produce enough insulin.Â
gliclazide belongs to a class of medications known as sulfonylureas, which work by stimulating the release of insulin from the beta cells of the pancreas. This helps to increase the uptake and utilization of glucose by peripheral tissues such as muscle and adipose tissue, leading to a lowering of blood sugar levels.Â
gliclazide is typically used in combination with diet and exercise to improve blood sugar control in patients with type 2 diabetes. It may be used alone or in combination with other antidiabetic medications, such as metformin or insulin, depending on individual patient factors and the severity of the diabetes.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
